Sold as Triferic, Triferic Avnu. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 3 applications for Ferric Pyrophosphate Citrate (sold as Triferic, Triferic Avnu), first approved Jan 23, 2015, with 0 new uses approved and 0 published complete response letters.
| Jan 23, 2015 | TrifericNDA 206317 · New formulation or manufacturer | Rockwell Medical Inc | 7 | Discontinued |
| Apr 25, 2016 | TrifericNDA 208551 · New dosage form | Rockwell Medical Inc | 2 | Discontinued |
| Mar 27, 2020 | Triferic AvnuNDA 212860 · New dosage form | Rockwell Medical Inc | 1 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA